Aslani, Nikka M.
HRN: 21-81-63 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/25/2025
CEFTRIAXONE 1G (VIAL)
01/24/2025
01/31/2025
IV
340mg
Q12h
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes